Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1HER2 Positive Esophagogastric Cancer 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Esophageal Cancer 1

Interventions

Cisplatin 66Paclitaxel 43Radiotherapy 39Carboplatin 29Fluorouracil 27Drug Therapy 20Irinotecan 16toripalimab 15pembrolizumab 15tislelizumab 14camrelizumab 13sintilimab 12Radiotherapy, Intensity-Modulated 11Albumin-Bound Paclitaxel 11S 1 (combination) 10Capecitabine 10130-nm albumin-bound paclitaxel 10apatinib 9Radiation 9Oxaliplatin 9Neoadjuvant Therapy 9Esophagectomy 9Docetaxel 9nimotuzumab 8TP protocol 8Cetuximab 8anlotinib 7Nivolumab 7nedaplatin 6Taxes 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Squamous Cell Carcinoma × Combined Modality Therapy × Clear all
NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡